Associate Principal Scientist, in Vivo Pharmacology

Merck Merck · Pharma · CA

This role focuses on developing in vivo pharmacology strategy and pharmacodynamics (PD) and efficacy models for cardiometabolic, renal, and respiratory diseases, as well as establishing quantitative PK/PD relationship and preclinical proof-of-concept. The scientist will apply knowledge of translational animal models, in vivo technology platforms, and quantitative pharmacology to advance therapeutic programs. Responsibilities include driving in vivo pharmacology strategy, leading model development & validation, collaborating with cross-functional groups, and managing external partners.

What you'd actually do

  1. Drive in vivo pharmacology strategy: Act as a scientific leader, defining and executing in vivo model development and pharmacology strategy for preclinical programs.
  2. Leverage disease area expertise for project support: Apply relevant knowledge and expertise in the pathogenesis of cardiometabolic, renal, or respiratory disorders to guide model selection and prioritization.
  3. Lead model development & validation: Drive the development, characterization, and selection of relevant in vivo models for target validation, compound screening and characterization, and mechanism-of-action studies.
  4. Collaborate with cross-functional groups (Biology, Med Chem, DMPK, Safety, etc.) to enable a comprehensive pharmacology strategy that enables robust assessment of target engagement, in vitro/in vivo correlation, PK/PD relationship, and human dose projection.
  5. Data analysis, interpretation, and reporting: Perform rigorous data analysis, interpret key findings, and translate complex results into actionable insights that inform on project decisions.

Skills

Required

  • Quantitative and translational pharmacology expertise
  • in vitro/in vivo correlation
  • PK/PD
  • translational biomarker
  • human dose projection
  • preclinical in vivo model development and implementation
  • rodent surgical skills for cardiometabolic, renal, or respiratory disease models
  • animal studies to evaluate target engagement, PK/PD, efficacy and safety profiles of drug candidates
  • in vivo and ex vivo techniques
  • complex preclinical projects management
  • cross-functional matrix environment collaboration
  • Biomarker Research
  • Cardiovascular Diseases
  • Cardiovascular Physiology
  • Cardiovascular Research
  • In Vivo Pharmacology
  • Pharmacology
  • Renal Physiology
  • Respiratory Pharmacology
  • Translational Pharmacokinetics and Pharmacodynamics (PKPD)

Nice to have

  • in vivo imaging techniques (ultrasound, MRI, optical imaging, etc.)
  • multiple therapeutic modalities (small molecule, peptide, biologic, etc.)